Adenosine deaminase inhibitors: Their role in chemotherapy and immunosuppression

Cancer Chemotherapy and Pharmacology

Volumn 4, Issue 4, 1980, Pages 227-235

  Glazer, Robert I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE DEAMINASE; ADENOSINE DERIVATIVE; COFORMYCIN; PENTOSTATIN;

CANCER CHEMOTHERAPY; DRUG METABOLISM; ENZYME INHIBITION; IMMUNOSUPPRESSIVE TREATMENT; PHARMACOKINETICS; REVIEW; STRUCTURE ACTIVITY RELATION; THERAPY;

ADENOSINE; ADENOSINE DEAMINASE; ANIMAL; ANTINEOPLASTIC AGENTS; DEOXYADENOSINES; DRUG SYNERGISM; HUMAN; IMMUNOSUPPRESSIVE AGENTS; KINETICS; NUCLEOSIDE DEAMINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0019206846     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00255266     Document Type: Review

References (96)

1. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2′-deoxycoformycin
2. Some aspects of the pharmacology of the adenosine deaminase inhibitors 2′-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine
3. Recovery of 2′-deoxycoformycin-inhibited adenosine deaminase in mouse erythrocytes and leukemia L1210 in vivo
4. Tight-binding inhibitors. IV. Inhibition of adenosine deaminases by various inhibitors
5. Potent inhibition of muscle 5′-AMP deaminase by the nucleoside antibiotics coformycin and deoxycoformycin
6. Adenosine deaminase from human erythrocytes: purification and effects of adenosine analogs
7. Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic dispositon of adenine arabinoside (vidarabine)
8. Determination of plaque inhibitory activity of adenine arabinoside (9-β- d-arabinofuranosyladenine) for herpes viruses using an adenosine deaminase inhibitor
9. Studies of the relationship between adenosine deaminase and immune function
10. Effects of 2′-phosphate, and 1-β- d-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia L1210
11. Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis
12. Enhancement of 9-β- d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2′-deoxycoformycin
13. Antiproliferative effect of 9-β- d-arabinofuranosyladenine 5′-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture
14. Tight-binding inhibitors. III. A new approach for the determination of competition between tight-binding inhibitors and substrates-inhibition of adenosine deaminase by coformycin
15. Tight-binding inhibitors. II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin
16. Effect of an adenosine deaminase inhibitor on the uptake and metabolism of arabinosyl adenine (vidarabine) by intact human erythrocytes
17. Adenosine deaminase inhibition for immunosuppression
18. Enzyme inhibition titration assay for 2′-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats
19. Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency
20. Adenosine deaminase inhibitors: differential effects on multiple forms of adenosine deaminase
21. Structural requirements of nucleosides for binding by adenosine deaminase
22. Human deaminase binding protein. Assay, purification and properties
23. Nucleoside analogs with selective antiviral activity
24. (S)-9-(2,3-dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity
25. Overproduction of adenine deoxynucleosides and deoxynucleotides in adenosine deaminase deficiency with severe combined immunodeficiency disease
26. Specificity of adenosine deaminase toward adenosine and 2′-deoxyadenosine analogues
27. Adenylate deaminase: potent inhibition by 2′-deoxycoformycin 5′-phosphate
28. The effects of 2′-deoxycoformycin on the action of cordycepin on nuclear RNA synthesis in regenerating liver
29. Inhibitory effects of cordycepin on cyclic nucleotide-dependent and cyclic nucleotide-independent protein kinases
30. Cordycepin and xylosyladenine: inhibitors of methylation of nuclear RNA
31. Evidence that xylosyladenine affects methylation by inhibition of S-adenosyl- l-methionine synthesis
32. Potentiation by 2′-deoxycoformycin of the inhibitory effect of 3′ deoxyadenosine (cordycepin) on nuclear RNA synthesis in L1210 cells in vitro
33. Adenosine metabolism in cultured lymphoid cells
34. Specificity of adenosine deaminase inhibitors
35. Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine and adenine arabinoside
36. Adenine and adenosine are toxic to human lymphoblast mutants defective in purine salvage enzymes
37. Adenosine deaminase deficiency and immunodeficiencies
38. 6Biosynthesis of S- N-methyl-adenosylhomocysteine, an inhibitor of RNA methyltransferase
39. Enhancement of the biological activity of cordycepin (3′-deoxyadenosine) by the adenosine deaminase inhibitor 2′-deoxycoformycin
40. Treatment of acute lymphoblastic leukemia with 2′-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition
41. S-Adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin
42. Role of S-adenosylhomocysteine in adenosine-mediated toxicity in cultured mouse T lymphoma cells
43. Inhibition of adenosine deaminase in vivo in CBA-J mice by erythro-9-(2-hydroxy-3-nonyl) adenine and its metabolic consequences
44. Toxicities of adenosine and 2′-deoxyadenosine in L cells treated with inhibitors of adenosine deaminase
45. Therapeutic effects of 9-β- d-arabinofuranosyladenine and 2′-deoxycoformycin combinations on intracerebral leukemia
46. Inhibition of the phosphorylation of non-histone chromosomal proteins of rat liver by cordycepin and cordycepin triphosphate
47. Inhibition of the phosphorylation of non-histone chromosomal proteins by cordycepin and xylosyladenine in L1210 cells in vitro
48. Enhancement of the antitumor activity of arabinofuranosyladenine by 2′-deoxycoformycin
49. Deoxyadenosine metabolism and toxicity in cultured L5178Y cells
50. Inhibition for immunosuppression
51. Effect of an adenosine deaminase inhibitor on survival of mouse pancreatic islet allografts
52. Use of microbiologic and enzymatic assays in studies on the disposition of 2′-deoxycoformycin in the mouse
53. -9-(2-hydroxy-3-nonyl) [14Metabolism and disposition of erythroC]adenine in the Rhesus monkey
54. Influence of coformycin on the cytostatic activity of 9-β- d-arabinofuranosyladenine and adenosine in mouse L5178Y cells
55. Structure of coformycin, an unusal nuceloside of microbial origin
56. Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues
57. Potentiation by 2′-deoxycoformycin of the inhibitory effect of xylosyladenine on nuclear RNA synthesis in L1210 cells in vitro
58. The use of high-pressure liquid chromatography in research on purine nucleoside analogs
59. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells
60. Biochemical basis of the increased activity of 9-β- d-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase
61. Comparison of the activity of 2′-deoxycoformycin and erythro-9-(2-hydroxy-2-nonyl)adenine in vivo
62. Inhibition of Newcastle disease virion meassenger RNA-(guanine-7-)-methyltransferase by analogues of S-adenosylhomocysteine
63. Sinefungin, a potent inhibitor of virion mRNA-(guanine-7-)-methyltransferase, mRNA-(nucleoside-2′-)-methyltransferase, and viral multiplication
64. Purine reutilization in phytohemagglutinin-stimulated human T lymphocytes
65. Tight-binding inhibitors. VI. Interactions of deoxycoformycin and adenosine deaminase in intact human erythrocytes and sarcoma 180 cells
66. Analysis by high-pressure liquid chromatography of 9-β- d-arabinofuranosyladenine 5′-triphosphate levels in murine leukemia cells
67. Mode of inhibition of coformycin on adenosine deaminase
68. Enzyme inhibitors 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines
69. Enzyme inhibitors. V. The syntheses of 6-substituted-(9-hydroxyalkyl)-purines and their evaluation as inhibitors of adenosine deaminase
70. Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency
71. Effect of 2′-deoxycoformycin on the biologic half life of 9-β- d-arabinofuranosyladenine 5′-triphosphate in CHO cells
72. A role for purine metabolism in the immune response: adenosine deaminase activity and deoxyadenosine catabolism
73. Inhibition of brain adenosine deaminase by 2′-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine
74. Effect of erythro-9-(2-hydroxy-3-nonyl)adenine on purine and pyrimidine metabolism in the human peripheral lymphocyte during the early phases of phytohemagglutin-mediated blastogenesis
75. Effect of a novel adenosine deaminase inhibitor (Co-vidarabine, Co-V) upon the antiviral activity in vitro and in vivo of Vidarabine (Vira-A) for DNA virus replication
76. Deoxyadenosine antagonism on the antiviral activity of 9-β- d-arabinofuranosyladenine and 9-β- d-arabinofuranosylhypoxanthine
77. In vivo toxicity to lymphoid tissue by 2′-deoxycoformycin
78. 2′-Deoxycoformycin: Phase I trial and clinical pharmacology
79. Role of nonhistone chromosomal proteins in the regulation of histone gene expression
80. Effects of 2′-deoxycoformycin and erythro-9-(2-hydroxy-2-nonyl)adenine on plasma levels and urinary excretion of 9-β- d-arabinofuranosyladenine in the mouse
81. Effects of 2′-deoxycoformycin infusion on mouse adenosine deaminase
82. Characterization of adenosine deaminase from normal colon and colon tumors. Evidence for tumor-specific variants
83. Studies on the effects of infusion of enzyme inhibitors on mouse adenosine deaminase
84. The effect of nucleosides and deoxycoformycin on adenosine and deoxyadenosine inhibition of human lymphocyte activation
85. Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease
86. Molecular form of adenosine deaminase in severe combined immunodeficiency
87. The metabolism of 2′-deoxycoformycin by L1210 cells in vitro
88. Antiviral activity of an adenosine deaminase inhibitor: decreased replication of herpes simplex virus
89. Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate
90. Influence of substituent ribose on transition state affinity in reactions catalyzed by adenosine deaminase
91. A novel adenosine and ara-A deaminase inhibitor, (R)-3-(2-deoxy-β- d- erythro-pentofuranosyl) 3,6,7,8-tetrahydroimidazo[4,5- d]diazepin-8-ol
92. A kinetic study of the deamination of some adenosine analogues. Substrate specificity of adenosine deaminase
93. Metabolic formation of nucleoside-modified analogues of S-adenosylmethionine
94. Potentiation by homocysteine of adenosine-stimulated elevation of cellular adenosine 3′,5′-monophosphate